Innate Pharma 9/17/2026 Earnings Report

Innate Pharma EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.34
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Innate Pharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $5.75 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Innate Pharma Announcement Details

• Date: 9/17/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Innate Pharma (OTCMKTS:IPHYF) is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.

The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing. Additional preclinical and clinical candidates aim to engage macrophages and other innate immune effectors. Innate Pharma pursues both monotherapy and combination strategies, advancing collaborations with global partners to evaluate its molecules alongside established cancer treatments.

Innate Pharma serves a global patient community through strategic partnerships and research alliances. The company has established joint development agreements with major pharmaceutical firms to accelerate clinical trials and broaden the geographic reach of its investigational therapies. In addition to its Marseille headquarters, Innate Pharma maintains a presence in the United States to support North American clinical and regulatory activities.

Under the leadership of Chief Executive Officer Mondher Mahjoubi and a management team with deep experience in immunology and drug development, Innate Pharma continues to expand its research capabilities and manufacturing infrastructure. With a history of pioneering work in the innate immune checkpoint field, the company seeks to deliver first-in-class or best-in-class immunotherapies that address unmet needs in cancer and beyond.